| Biomarker ID | 218 |
| PMID | 17713630 |
| Year | 2007 |
| Biomarker | Endothelial cell-specific molecule 1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Cell Lines |
| Subjects | Rat |
| Regulation | Upregulated in MAT-LyLu (23 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include: Extracellular/ECM; Cell motility;Defense response; Development; MAP kinase phosphatase activity;Oxidoreductase activity; Proteolysis and peptidolysis; Regulation of cell cycle /proliferation; Regulation of transcription/ DNA-binding; Transporter activity; Ubiquitin activity; Calcium ion binding; Carboxylesterase activity; DNA repair; Enzyme inhibitor activity; Glucuronosyltransferase activity; Receptor activity; Growth factor; Induction of apoptosis; Kinesin complex; Ligase activity; Lactate dehydrogenase activity; Phosphatase activity; Transcription coactivator activity; Transferase activity; Alcohol dehydrogenase activity; Hydrolase activity; Fatty acid metabolism; |
| Experiment | MAT-LyLu Vs G Cell Lines |
| Type of Biomarker | Prognostic |
| Cohort | Dunning rat tumor cell sublines, G (non metastatic) and MAT-LyLu (highly metastatic) were grown |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.00995283 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Validated on qRT-PCR |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on human patient cohort |
| Technical Name | NA |